Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

doi:10.1186/s13045-020-00964-5

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

Journal of hematology & oncology - 8 Oct 2020

Yilmaz Musa, Alfayez Mansour, DiNardo Courtney D, Borthakur Gautam, Kadia Tapan M, Konopleva Marina Y, Loghavi Sanam, Kanagal-Shamanna Rashmi, Patel Keyur P, Jabbour Elias J, Garcia-Manero Guillermo, Pemmaraju Naveen, Pierce Sherry A, Ghayas Issa, Short Nicholas J, Montalban-Bravo Guillermo, Takahashi Koichi, Assi Rita, Alotaibi Ahmad S, Ohanian Maro, Andreeff Michael, Cortes Jorge E, Kantarjian Hagop M, Ravandi Farhad, Daver Naval G

Abstract excerpt

BACKGROUND: Second-generation FLT3-inhibitors (FLT3i) demonstrated single-agent composite CR rates (CRc) of 45-55% in patients with relapsed/refractory (R/R) FLT3-mutated AML in phase II/III trials. However, > 85% of patients treated were prior FLT3i naïve. The response rates to sequential FLT3i exposure remain poorly defined. METHODS: We retrospectively reviewed patients with FLT3-mutated AML between November...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Antineoplastic Combined Chemotherapy Protocols

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33032648
DOI: 10.1186/s13045-020-00964-5
PMCID: PMC7542942

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.PMID 33032648Read ↗

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia.Semantic proximity Read ↗

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.Semantic proximity Read ↗

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity Read ↗

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.Semantic proximity Read ↗

FLT3 targeting in the modern era: from clonal selection to combination therapies.Semantic proximity Read ↗

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.Semantic proximity Read ↗

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.Semantic proximity Read ↗

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Semantic proximity Read ↗

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.Semantic proximity Read ↗

Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.